Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities

Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies

(2011) Alfred Schnueriger et al.   MOLECULAR IMMUNOLOGY

Advances in the assessment and control of the effector functions of therapeutic antibodies

(2011) Xu-Rong Jiang et al.   NATURE REVIEWS DRUG DISCOVERY

The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy

(2009) J Griggs et al.   BRITISH JOURNAL OF CANCER

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2009) Neil L. Spector et al.   JOURNAL OF CLINICAL ONCOLOGY

Defucosylated Anti-CCR4 Monoclonal Antibody Exerts Potent ADCC against Primary ATLL Cells Mediated by Autologous Human Immune Cells in NOD/Shi-scid, IL-2R null Mice In Vivo

(2009) A. Ito et al.   JOURNAL OF IMMUNOLOGY

Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action

(2009) Royston Jefferis   TRENDS IN PHARMACOLOGICAL SCIENCES

Terminal sugars of Fc glycans influence antibody effector functions of IgGs

(2008) T Shantha Raju   CURRENT OPINION IN IMMUNOLOGY

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY